Compact viability ProTom’s Radiance 330 modular and compact proton therapy system positions the company well for clinics with space constraints or existing linac vaults, suggesting sales opportunities with mid-size cancer centers seeking upgrade paths or facility expansions.

Flexible integration The partnership with Leo Cancer Care to integrate Radiance 330-C with upright positioning and imaging highlights a market opportunity in turnkey solutions that reduce patient setup time and boost workflow efficiency, appealing to hospitals aiming to differentiate through streamlined operations.

Accessibility push Recent launches of a fixed-beam proton system and the Radiance 330-C emphasize a strategy to broaden proton therapy adoption, presenting cross-sell opportunities to clinics evaluating more modular or budget-friendly radiotherapy options.

Financial upside With a reported revenue range of 25–50 million and a funding level of 32 million, ProTom demonstrates a credible growth trajectory and investor backing, which can be leveraged in conversations with financing teams and hospital administrators seeking ROI and capital planning assurances.

Industry momentum Active press coverage and multiple recent announcements since 2021 indicate ongoing market interest in compact and flexible proton therapy tech, suggesting prospect lists should include institutions exploring accelerator-based treatments and partnerships for technology refresh cycles.